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AbsTrACT
Objective To assess the prognostic value of practice 
effect on paced auditory serial addition Test (pasaT) in 
multiple sclerosis.
Methods We compared screening (day −14) and 
baseline (day 0) pasaT scores of 1009 patients from the 
FTY720 Research evaluating effects of Daily Oral therapy 
in Multiple sclerosis (FReeDOMs) trial. We grouped 
patients into high and low learners if their pasaT score 
change was above or below the median change in their 
screening pasaT quartile group. We used Wilcoxon test 
to compare baseline disease characteristics between 
high and low learners, and multiple regression models to 
assess the respective impact of learning ability, baseline 
normalised brain volume and treatment on brain volume 
loss and 6-month confirmed disability progression over 
2 years.
results The mean pasaT score at screening was 
45.38, increasing on average by 3.18 from day −14 
to day 0. high learners were younger (p=0.003), had 
lower expanded Disability status scale score (p=0.031), 
higher brain volume (p<0.001) and lower T2 lesion 
volume (p=0.009) at baseline. Learning status was 
not significantly associated with disability progression 
(hR=0.953, p=0.779), when adjusting for baseline 
normalised brain volume, screening pasaT score and 
treatment arm. however, the effect of fingolimod on 
disability progression was more pronounced in high 
learners (hR=0.396, p<0.001) than in low learners 
(hR=0.798, p=0.351; p for interaction=0.05). Brain 
volume loss at month 24 tended to be higher in low 
learners (0.17%, p=0.058), after adjusting for the same 
covariates.
Conclusions short-term practice effects on pasaT are 
related to brain volume, disease severity and age and 
have clinically meaningful prognostic implications. high 
learners benefited more from fingolimod treatment.
InTrOduCTIOn
Multiple sclerosis (MS) is a chronic and debilitating 
disease affecting mainly adults early in their life. It is 
a progressive disease characterised by the formation 
of lesions in the brain and spinal cord. Symptoms 
of the disease are widespread and largely depen-
dent on the location of the lesions and the extent 
of inflammatory and degenerative pathology within 
the central nervous system. The majority of patients 
manifest with a relapsing-remitting disease course 
but progress to a more progressive and degenerative 
stage of the disease within a decade.1 In addition to 
motor symptoms, cognitive impairment is prevalent 
in all stages of MS,2 3 including early relapsing-re-
mitting disease and clinically isolated syndromes.4–7 
The cognitive functions preferentially affected in 
MS include attention, information processing effi-
ciency and speed, executive functioning, and long-
term memory.3 Over the last two decades, the Paced 
Auditory Serial Addition Test (PASAT), as part of the 
Multiple Sclerosis Functional Composite score, has 
been the most commonly used test to evaluate atten-
tional function in MS clinical trials.8–10 However, 
at repeated administrations, a significant practice 
effect has been reported resulting in increased mean 
PASAT scores in both the active and control groups 
over time.11 12 This practice effect makes interpre-
tation of true treatment effects difficult10 13 and 
accentuates the ceiling effect in patients with higher 
baseline scores who anyway have limited room for 
further improvement in contrast to those with low 
baseline scores who can further improve at subse-
quent visits.13 Nevertheless, PASAT scores correlate 
with brain volume (BV) cross-sectionally.14 Brain 
volume loss (BVL) is increasingly recognised as a 
predictor of disability progression,15–17 but inter-
pretation of the longitudinal association to PASAT 
scores is complicated by the observed practice 
effects. Recent studies have suggested that higher 
BV and cognitive reserve can be buffers to acceler-
ated disability progression.18 19 We investigated the 
relation of the PASAT practice effect as a measure 
of learning ability and cognitive reserve with other 
disease characteristics, and determined whether this 
practice effect—as a dynamic measure—can inform 
prognosis of patients with MS.
In patients who participated in the FTY720 
Research Evaluating Effects of Daily Oral therapy 
in Multiple Sclerosis (FREEDOMS) trial comparing 
fingolimod and placebo, we (1) assessed and quan-
tified learning ability as expressed by change in 
PASAT score after short-term repeated administra-
tion accounting for baseline cognitive performance; 
(2) investigated the correlation of practice effect 
with baseline MS disease characteristics; and (3) 
determined whether the practice effect can predict 
on-study BVL, future disability worsening and 
treatment effect.
MeThOds
study design and patients
This is a post-hoc analysis of data from the FREE-
DOMS20 study (n=1009, complete data set), a 
phase III, randomised, placebo-controlled study 
of fingolimod in patients with relapsing-remitting 
39sormani Mp, et al. J Neurol Neurosurg Psychiatry 2019;90:38–43. doi:10.1136/jnnp-2018-319129
Multiple sclerosis
Figure 1 paced auditory serial addition Test (pasaT) score change from screening to baseline: practice effect. patients with baseline pasaT score of 60 
(n=12) who did not change between screening and baseline were classified as ’high learners’.panel a shows mean pasaT change, panel B shows screening 
pasaT quartiles and, panel c shows correlation of pasaT screening score with practice effect.
multiple sclerosis (RRMS). The study design and inclusion/
exclusion criteria of the FREEDOMS study have been previ-
ously described.20 In brief, the study included patients diagnosed 
with RRMS (according to the revised McDonald criteria21) 
aged 18–55 years who had a score of 0–5.5 on the Expanded 
Disability Status Scale (EDSS), and one or more documented 
relapses in the past year, or two or more relapses in the past 2 
years prior to randomisation. Patients were to be neurologically 
stable with no evidence of relapse or corticosteroid treatment 
within 30 days prior to randomisation. Eligible patients were 
randomised (1:1:1) to receive either fingolimod 0.5 or 1.25 mg 
once daily or placebo for 2 years.20 In all the analyses the two 
treatment arms are pooled together.
Assessments
Standardised neurological assessments, including determination 
of EDSS score, were performed at baseline and every 3 months. 
MRI scans were obtained at baseline and months 6, 12 and 24 
or at the end of study in patients prematurely discontinuing the 
study. MRI lesion activity and BVL were assessed at a central 
reading site (Medical Image Analysis Center, Basel, Switzer-
land) that remained blinded for clinical data and randomisa-
tion. Normalised brain volume (NBV) was assessed at baseline 
using ‘Structural Image Evaluation, using Normalization, of 
Atrophy, Cross-sectional’ (SIENAX). PASAT was administered 
at screening (day −14; two trials) and at baseline (day 0; one 
test). Per cent brain volume change (PBVC) between baseline and 
month 24 was determined using ‘Structural Image Evaluation, 
using Normalization, of Atrophy’ (SIENA). Disability worsening 
was defined as a ≥1-point increase in the EDSS score sustained 
for ≥6 months (1.5 points if baseline EDSS=0).
statistical analysis
Patients were divided into four groups by quartiles of the PASAT 
score at screening (day −14; average of two trials), and the 
median value of PASAT change for each quartile was calculated. 
In each of these four groups, patients were further defined as 
‘high learners’ if they had a PASAT score improvement above 
their group’s median, or ‘low learners’ if they had a PASAT 
score change below the median of their quartile group. To miti-
gate ceiling effects patients with screening PASAT scores of 60 
(maximum value) and no change at baseline were counted as 
‘high learners’. By defining learning ability within the screening 
quartile groups, we could take into account the fact that patients 
with higher screening scores have less room for further improve-
ment (ceiling effect) compared with those who started with a 
low screening score.
The Wilcoxon rank-sum test was used to compare different 
baseline characteristics (age, clinical disease burden (EDSS), T2 
lesion volume (T2LV) and NBV) between high and low learners. 
A multivariate logistic regression model with a forward selection 
was run to select factors independently associated with learning 
ability. Pearson’s correlation (r) was used to measure the correla-
tions between PASAT score at screening and change in PASAT 
score with baseline age, EDSS, disease duration, T2 lesion load 
and NBV. A Cox proportional hazard model was used to assess if 
there was a difference in the risk of 6-month confirmed disability 
progression (CDP) over 2 years between high and low learners 
after adjusting for fingolimod treatment, NBV and screening 
PASAT score. The Cox model was used to assess if treatment 
effect differed based on the high versus low learner status, by 
including a treatment-by-learning status interaction in the model. 
Finally, a linear regression model was used to determine whether 
learning ability between screening and baseline is predictive of 
the rate of PBVC over 2 years, after adjusting for fingolimod 
treatment, NBV and screening PASAT score.
resulTs
PAsAT practice effects
Overall, a mean improvement of 3.18 (SD=6.44) was noted in 
the PASAT score from screening (45.38 (11.24), day −14) to 
baseline (48.56 (11.07), day 0), compatible with the well-known 
practice effect (figure 1A). The median change in PASAT score 
from screening to baseline was 5.0 for Q1, 3.5 for Q2 and Q3, 
and 0.5 for Q4 (figure 1B). A total of 513 patients were included 
in the ‘high-learners’ group and 496 in the ‘low-learners’ group 
(figure 1B).
Correlations of baseline findings and practice effect
The baseline characteristics of the total analysis cohort by 
learning ability are reported in table 1.
The PASAT score at screening was positively correlated with 
baseline PASAT score (r=0.83, p<0.0001) and NBV (r=0.26, 
p<0.0001), and was inversely correlated with PASAT change/
practice effect (r=−0.31, p<0.0001; figure 1C). No correlation 
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Table 1 Baseline characteristics
Total high learners low learners P values
N=1009 n=513 n=496
Age, years 37.07 (8.72) 36.27 (8.90) 37.9 (8.45) 0.003
Disease duration since first symptoms 8.1 (6.6) 7.8 (6.3) 8.4 (6.87) 0.256
NBV, cm3 1517.24 (84.02) 1527.45 (81.02) 1506.68 (85.82) <0.0001
EDSS score 2.35 (1.28) 2.24 (1.21) 2.46 (1.35) 0.031
T2LV, mm3 6253.67 (7653.41) 5568.68 (6987.82) 6962.13 (8233.09) 0.009
Data presented as mean (SD), unless specified otherwise.
EDSS, Expanded Disability Status Scale; NBV, normalised brain volume; T2LV, T2 lesion volume.
Table 2 Univariate and multivariate analyses assessing the effects of baseline variables on 6-month CDP at 2 years
Covariate unit
univariate analysis Multivariate analysis
hr (95% CI) P values hr (95% CI) P values
Treatment (fingolimod vs placebo) – 0.55 (0.39 to 0.76) <0.001 0.56 (0.40 to 0.78) 0.001
NBV 100 mm3 0.72 (0.60 to 0.87) 0.001 0.76 (0.62 to 0.92) 0.006
Screening PASAT score 1 point 0.98 (0.97 to 0.99) 0.015 0.99 (0.98 to 1.01) 0.15
Learning ability (high vs low) – 0.88 (0.64 to 1.23) 0.46 0.95 (0.68 to 1.33) 0.78
CDP, confirmed disability progression; NBV, normalised brain volume; PASAT, Paced Auditory Serial Addition Test.
Figure 2 Differential treatment effect on risk of 6-month confirmed disability progression in low versus high learners. Treatment by learners interaction 
p=0.05.
was found between NBV and unadjusted PASAT change (r=0.02, 
p=0.48).
High learners were younger than low learners (p=0.003) and 
had higher NBV (p<0.001; table 1). Moreover, high learners had 
lower clinical (EDSS score, p=0.03) and MRI (T2LV, p=0.009) 
disease burden at baseline (table 1). The multivariate analysis 
showed that NBV has the strongest association with learning 
ability: the OR=1.35 (p<0.001) indicated a 35% increase in the 
probability to be a high learner for every increase of NBV by 
100 mm3.
disease outcomes and treatment effect by practice effect
The PASAT score at screening, treatment and NBV were all asso-
ciated with the probability of 6-month CDP in the univariate anal-
ysis, but when included in a multivariate model only treatment 
with fingolimod (HR 0.56, p<0.001 vs placebo) and NBV (HR 
0.76, p=0.006) were independently associated with a decreased 
risk of 6-month CDP (table 2). The risk of 6-month CDP was not 
significantly affected by the learning ability. However, when a 
model with a treatment-by-learner status interaction was applied, 
the interaction term was significant (p=0.05), indicating that the 
fingolimod treatment effect is stronger in high learners (60% 
risk reduction, HR=0.40, p<0.001) than in low learners (21% 
risk reduction, HR=0.79, p=0.35; figure 2).
PBVC over 2 years was lower in patients treated with fingo-
limod (PBVC=−0.87%) than those treated with placebo 
(PBVC=−1.28%; difference −0.39%, p<0.001; table 3). 
It was also lower in patients with higher NBV values at base-
line (p=0.006) and higher screening PASAT scores (p=0.038) 
(table 3). Patients from the high-learner group experienced less 
PBVL than those from the low-learner group (p=0.01, table 3). 
Treatment, NBV, screening PASAT score and learning ability all 
correlated with PBVL in both the univariate and multivariate 
analyses. Being in the high PASAT learner group was therefore 
independently associated with a lower PBVL throughout the 
study period, and even after adjusting for screening PASAT score 
and baseline NBV the difference (−0.17%) remained borderline 
significant (p=0.058; figure 3).
dIsCussIOn
The practice effect seen with PASAT is usually considered a 
limitation of this test, because it can potentially confound the 
interpretation of a treatment effect on cognitive performance in 
clinical trials.22 Because this effect is most pronounced in the 
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Table 3 Univariate and multivariate analyses assessing the effects of baseline variables on 2-year PBVC
Covariate unit
univariate analysis Multivariate analysis
beta* P values beta* P values
Treatment (fingolimod vs placebo) – 0.41 (0.22–0.59) <0.001 0.39 (0.21–0.57) 0.001
NBV 100 mm3 0.34 (0.24–0.45) <0.001 0.30 (0.19–0.40) 0.006
Screening PASAT score 1 point 0.015 (0.007–0.023) <0.001 0.008 (0.001–0.016) 0.038
Learning ability (high vs low) – 0.23 (0.06–0.41) 0.01 0.17 (0.006–0.34) 0.058
*Beta: PBVC change associated with the 1-unit change of the independent variable.
NBV, normalised brain volume; PASAT, Paced Auditory Serial Addition Test; PBVC, per cent brain volume change.
Figure 3 Brain volume loss in low versus high learners (per treatment group). pBVc, per cent brain volume change.
first repetitions of the test, most studies require to repeat the 
test at least two to three times before treatment start. However, 
the improvement in performance over time observed at repeated 
administrations is reflective of active learning.13 23 The driving 
hypothesis of our study was that this learning effect induced by 
repeated testing, besides being an interfering variable, would by 
itself be a valuable measure of cognitive performance. To date 
the potential clinical relevance and implications of this learning 
effect and the association of practice effect and learning ability 
with disease outcomes have been poorly investigated. A study in 
patients with clinically isolated syndrome on disease-modifying 
therapy assessed the temporal association between MRI measures 
and PASAT performance and reported higher PASAT learning 
effects in patients with lower rates of grey matter atrophy.24
Based on a large, randomised controlled study, we confirm 
the existence of a significant practice effect on PASAT scores13; 
patients’ cognitive performance improved on average when the 
test was repeated 14 days after the first PASAT trial. Patients 
with high PASAT scores at screening exhibited lower PASAT 
changes compared with those with a low screening PASAT score. 
This inverse correlation indicates the need to adjust the PASAT 
change for screening PASAT scores in order to correctly identify 
the patients who show improvements at baseline. Assessing the 
change in PASAT score, as compared with the median screening 
PASAT score within a quartile, allowed to quantify the learning 
ability as a measure of cognitive reserve adjusting for the impact 
of baseline performance.
Patient baseline demographic and disease characteristics are 
also associated with cognitive performance as measured by 
PASAT. High PASAT scores at baseline corresponded to younger 
patients who also had high NBV and lower disease burden at 
baseline. Thus, the learning ability of patients with RRMS, as 
measured using the practice effect on PASAT, is reflective of age 
and MS disease severity (EDSS score, BV and T2LV) at baseline. 
It is known that performance in PASAT is influenced by intelli-
gence and mathematical ability,13 25 which could contribute to 
the ceiling effect. Also, comorbidities such as depression and/
or anxiety13 and occurrence of a recent MS relapse may affect 
the cognitive status of the patient. However, it is difficult to 
measure the impact of these variables, and therefore adjustment 
for these factors is difficult to achieve. The FREEDOMS trial did 
not include patients with pre-existing serious psychiatric condi-
tions. Although assessment of neurological disability (changes in 
functional system and EDSS score) was performed to confirm a 
relapse, neurocognitive status was not evaluated at the time or 
immediately after the relapse. Deficits in information processing 
speed and working memory is the most prominent aspect of 
cognitive impairment in patients with MS. The association of 
cognitive status and disability progression as assessed by change 
in EDSS score is not clearly reported in the literature, and is 
further complicated by the fact that there is lack of a standard 
tool to measure cognitive impairment. It has been reported that 
patients with cognitive impairment at baseline had worsening 
EDSS score26 27 and were at significantly higher risk of reaching 
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EDSS >4 as compared with cognitively preserved patients.28 
However, some studies suggest that cognitive decline is better 
correlated with brain atrophy measures, particularly deep grey 
matter atrophy, than EDSS progression.29 30
It has been previously reported that treatment effect on brain 
atrophy correlates with the effect on disability progression over 
2 years and predicts future disability progression independent of 
the effect on active MRI lesions in patients with RRMS.31 Further-
more, a correlation between treatment effect of fingolimod on 
BVL and its corresponding effect on future disability progression 
has also been reported.32 In patients treated with fingolimod, 
2-year disability progression was associated with the rate of BVL 
over 2 years, and treatment effect of fingolimod on PBVC was 
predictive of future disability.32 We now report the association 
of fingolimod treatment effect on disability progression based 
on the learning ability of patients. In both high and low learners, 
treatment with fingolimod reduced the risk of disability progres-
sion, with stronger effects in high learners. After adjusting for 
the practice effect, high learners showed better prognosis in 
terms of both BVL and CDP over 2 years. After accounting for 
the treatment effect of fingolimod and baseline NBV, PASAT and 
learning ability had however no additional explanatory value for 
the prediction of disability progression in patients with RRMS. 
The lack of correlation between unadjusted PASAT change 
and NBV was due to the dependence of PASAT change on the 
screening value. This supports the importance and stronger 
relevance of NBV (also called as brain reserve) in predicting 
disability progression in patients with RRMS compared with 
PASAT. Our data contradict the findings of Raghupathi et al33 
that stipulate PASAT as an independent predictor of disability 
progression in an integrated analysis including data from the 
AFFIRM, DEFINE, CONFIRM and ADVANCE trials. Others 
have reported that higher brain reserve attenuates the impact 
of disease on cognitive efficiency, as measured by performance 
in PASAT.34 35 Our results, along with the findings from these 
previous reports, further suggest that both brain reserve and 
cognitive reserve protect against disease-related disability and 
cognitive decline. Interestingly, baseline PASAT score, learning 
ability and treatment were independent predictors of BVL.
In conclusion, our results suggest that greater cognitive 
reserve, as indicated by high baseline PASAT score, is a good 
prognostic indicator and that a greater ability to learn is associ-
ated with better treatment response and better disease outcomes 
in the future.
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